New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction

Pembrolizumab for head and neck cancer

Genomic marker predicts anti-PD-1 response in several cancers

Nivolumab extends survival for NSCLC

Promising results for nivolumab in advanced liver cancer

Nivolumab extends survival for patients with the most common lung cancer

Pembrolizumab shows promising activity against head and neck cancer

Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial

Genomic marker predicts anti-PD-1 response in several cancers